Guardant Health, Inc. reported significant financial results for the second quarter of 2025, with total revenue reaching $232.1 million, a 31% increase from $177.2 million in the same period last year. For the first half of 2025, revenue totaled $435.6 million, up 26% from $345.7 million in the first half of 2024. The growth was primarily driven by a 22% increase in oncology revenue, which amounted to $158.7 million, attributed to a rise in test volume and improved reimbursement rates for its Guardant360 tests. The company also generated $56.0 million from biopharma and data services, reflecting a 28% increase, while screening revenue contributed $14.8 million, marking its first revenue from the newly launched Shield screening tests.
Despite the revenue growth, Guardant Health reported a net loss of $99.9 million for the second quarter, slightly down from a loss of $102.6 million in the prior year. For the first half of 2025, the net loss was $195.1 million, compared to $217.6 million in the same period of 2024. The increase in operating expenses, which totaled $338.5 million for the quarter, was driven by higher costs in research and development, sales and marketing, and general administrative expenses. Notably, sales and marketing expenses surged by 46% to $119.6 million, reflecting the company's investment in expanding its commercial team and marketing efforts for the Shield product launch.
In terms of operational metrics, Guardant Health reported approximately 64,000 oncology tests performed in the second quarter, up from about 49,400 in the same quarter of 2024. The company also noted a significant increase in its cash position, with cash, cash equivalents, and restricted cash totaling $735.5 million as of June 30, 2025, compared to $525.5 million at the end of 2024. This increase was bolstered by cash provided from investing activities, primarily from the maturities of marketable debt securities.
Strategically, Guardant Health has made notable advancements, including the FDA approval of its Shield blood test for colorectal cancer screening, which became commercially available in August 2024. The test is now covered by Medicare, enhancing its market potential. Additionally, the company is expanding its international presence, having established partnerships in Europe and Asia to broaden its reach. Looking ahead, Guardant Health anticipates continued growth in revenue driven by increased test volumes and expanding payer coverage, although it acknowledges the inherent risks associated with reimbursement variability and market conditions.
Overall, while Guardant Health continues to face challenges related to operating losses, its strategic initiatives and revenue growth indicate a positive trajectory in the precision oncology market. The company remains focused on innovation and expanding its product offerings to enhance patient care and drive future growth.
About Guardant Health, Inc.
Guardant Health, Inc. is a precision oncology company providing blood and tissue tests for cancer detection, monitoring, and therapy selection. Its core offerings include liquid biopsies, early detection screens, and companion diagnostics, serving patients, clinicians, and biopharmaceuticals globally. The company leverages advanced sequencing, AI, and real-world data to improve cancer outcomes and supports drug development and research through its comprehensive testing platform.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.